Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?

RMD Open. 2022 May;8(1):e002203. doi: 10.1136/rmdopen-2022-002203.
No abstract available

Keywords: COVID-19; arthritis, rheumatoid; biological therapy; methotrexate; vaccination.

Publication types

  • Letter

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Immunomodulating Agents
  • Rheumatic Diseases* / drug therapy
  • SARS-CoV-2


  • COVID-19 Vaccines
  • Immunomodulating Agents